XTX Topco Ltd Makes New $267,000 Investment in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

XTX Topco Ltd purchased a new position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 31,573 shares of the specialty pharmaceutical company's stock, valued at approximately $267,000. XTX Topco Ltd owned approximately 0.06% of KalVista Pharmaceuticals as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the business. Legal & General Group Plc boosted its holdings in shares of KalVista Pharmaceuticals by 22.5% in the fourth quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company's stock valued at $69,000 after acquiring an additional 1,494 shares in the last quarter. Martin Worley Group purchased a new stake in KalVista Pharmaceuticals during the 4th quarter worth about $86,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of KalVista Pharmaceuticals by 24.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company's stock valued at $87,000 after buying an additional 2,043 shares during the period. SG Americas Securities LLC increased its stake in KalVista Pharmaceuticals by 10.0% in the fourth quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company's stock valued at $123,000 after purchasing an additional 1,319 shares during the last quarter. Finally, Intech Investment Management LLC grew its holdings in KalVista Pharmaceuticals by 58.5% in the fourth quarter. Intech Investment Management LLC now owns 17,204 shares of the specialty pharmaceutical company's stock valued at $146,000 after purchasing an additional 6,349 shares during the period.

Insiders Place Their Bets

In other KalVista Pharmaceuticals news, major shareholder Venrock Healthcare Capital Par bought 14,562 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, February 3rd. The shares were bought at an average price of $9.22 per share, with a total value of $134,261.64. Following the purchase, the insider now owns 5,012,796 shares of the company's stock, valued at $46,217,979.12. This trade represents a 0.29 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Benjamin L. Palleiko sold 5,104 shares of the firm's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $9.82, for a total value of $50,121.28. Following the completion of the transaction, the chief executive officer now owns 278,855 shares in the company, valued at $2,738,356.10. This represents a 1.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders purchased 261,055 shares of company stock worth $2,397,646 and sold 17,292 shares worth $184,625. Corporate insiders own 10.50% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on KALV. Citizens Jmp raised shares of KalVista Pharmaceuticals to a "strong-buy" rating in a research note on Friday, January 31st. HC Wainwright restated a "buy" rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a research note on Friday, March 14th. JMP Securities assumed coverage on shares of KalVista Pharmaceuticals in a report on Friday, January 31st. They set an "outperform" rating and a $19.00 price objective for the company. Needham & Company LLC restated a "buy" rating and set a $28.00 price objective on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 8th. Finally, Jones Trading reaffirmed a "buy" rating and set a $30.00 target price on shares of KalVista Pharmaceuticals in a report on Wednesday, March 26th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $24.83.

KalVista Pharmaceuticals Price Performance

Shares of NASDAQ KALV traded up $0.08 during mid-day trading on Tuesday, hitting $13.08. The company had a trading volume of 413,714 shares, compared to its average volume of 405,786. KalVista Pharmaceuticals, Inc. has a 12 month low of $7.30 and a 12 month high of $15.50. The firm has a market cap of $650.29 million, a P/E ratio of -3.59 and a beta of 0.39. The business's 50-day simple moving average is $11.66 and its 200-day simple moving average is $10.36.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).